Abstracts

Visual Inspection With Acetic Acid Is Good for Follow-up After Cryotherapy in HIV-Infected Women

Background: As See and Treat programs using VIA and cryotherapy gain popularity, knowing the appropriate follow-up is critical. Few studies have addressed the optimal follow-up for HIV-infected women after VIA and immediate cryotherapy. This study seeks to identify the optimal follow-up test to accurately detect persistent moderate/severe cervical dysplasia and cancer in HIV-infected women who…

HIV-1 Infection and Type-1 Interferon

Background: The type-1 interferons (IFNs) are pro-inflammatory cytokines that are effective suppressors of HIV-1 replication are produced at elevated levels during acute HIV-1 infection and are associated with increased viral loads during chronic infection. This presentation will review the biology of type-1 IFN and its interplay with HIV-1 infection in humans. Drawing upon data gleaned…

Dolutegravir in the French Early Access Program in Integrase HIV-2-Resistant Infected Patients

Background: Dolutegravir (DTG) is a second generation integrase inhibitors (INSTI), active in patients harboring first-generation INSTI resistant virus. In France, DTG is currently available in early access program (EAP) in salvage therapy. DTG has shown in vitro activity on HIV-2 isolates. We report preliminary safety and efficacy data of DTG containing regimens in HIV-2 infected…

RALTEGRAVIR-ASSOCIATED MUTATIONS IN HIV-2 CONFER CROSS-RESISTANCE TO DOLUTEGRAVIR IN VITRO

Background: Dolutegravir (S/GSK1349572) recently became the third integrase strand transfer inhibitor (INSTI) approved for antiretroviral therapy of HIV 1. Although dolutegravir and other INSTI might also be useful for treating HIV-2 infection, the clinical efficacy of dolutegravir has not been evaluated in HIV-2 patients, and data assessing the activity of the drug against HIV-2 in…

HIV-2 X4 Tropism Is Associated With Lower CD4 Cell Count in Treatment-Experienced Patients

Background: Genotypic tools for HIV-2 tropism determination have been recently established. In vitro studies have demonstrated that maraviroc has efficacy against HIV-2. Currently, maraviroc use is only considered in highly pre-treated HIV-2 patients. However, R5/X4 tropism distribution is still unknown during HIV-2 infection. The aim of this study was to describe HIV-2 tropism distribution in…